Ildong Pharmaceutical Co., Ltd.(KR:249420)
â‚©11,870.00-420.00 (-3.42%)
KR:249420
Ildong Pharmaceutical Co., Ltd. financials statements
â‚©11,870.00
At close:-420.00 (-3.42%)
Want to see KR:249420 full AI Analyst Report?
Ildong Pharmaceutical Co., Ltd. (249420) Ratios
Ildong Pharmaceutical Co., Ltd. Ratios
KR:249420's free cash flow for Q3 2026 was ₩12.49B. For the 2026 fiscal year, KR:249420's free cash flow was decreased by ₩-2.50B and operating cash flow was ₩14.99B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.96 | 0.90 | 0.68 | 0.89 | 0.83 |
| Quick Ratio | 0.53 | 0.58 | 0.44 | 0.58 | 0.60 |
| Cash Ratio | 0.28 | 0.26 | 0.15 | 0.16 | 0.37 |
| Solvency Ratio | 0.15 | 0.05 | -0.12 | -0.25 | -0.13 |
| Operating Cash Flow Ratio | 0.08 | 0.10 | -0.11 | -0.17 | -0.03 |
| Short-Term Operating Cash Flow Coverage | 0.16 | 0.22 | -0.19 | -0.38 | -0.09 |
| Net Current Asset Value | â‚© -111.55B | â‚© -182.99B | â‚© -201.31B | â‚© -175.55B | â‚© -246.84B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.26 | 0.35 | 0.35 | 0.32 | 0.32 |
| Debt-to-Equity Ratio | 0.61 | 1.28 | 1.25 | 1.09 | 1.48 |
| Debt-to-Capital Ratio | 0.38 | 0.56 | 0.56 | 0.52 | 0.60 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.26 | 0.02 | 0.08 | 0.28 |
| Financial Leverage Ratio | 2.33 | 3.66 | 3.61 | 3.43 | 4.64 |
| Debt Service Coverage Ratio | 0.25 | 0.22 | -0.19 | -0.68 | -0.43 |
| Interest Coverage Ratio | 1.42 | 0.73 | -3.63 | -7.49 | -5.15 |
| Debt to Market Cap | 0.10 | 0.55 | 0.40 | 0.22 | 0.24 |
| Interest Debt Per Share | 5409.72 | 8005.90 | 8414.75 | 8257.50 | 9952.15 |
| Net Debt to EBITDA | 2.14 | 3.97 | -3.11 | -1.93 | -0.89 |
| Profitability Margins | |||||
| Gross Profit Margin | 37.88% | 37.96% | 34.55% | 37.06% | 39.18% |
| EBIT Margin | 3.06% | 1.24% | -13.24% | -17.25% | -23.32% |
| EBITDA Margin | 7.04% | 5.46% | -8.53% | -12.62% | -18.09% |
| Operating Profit Margin | 3.06% | 2.13% | -8.89% | -11.50% | -9.71% |
| Pretax Profit Margin | 5.61% | -1.74% | -15.69% | -18.79% | -25.21% |
| Net Profit Margin | 4.88% | -0.74% | -13.14% | -22.29% | -17.80% |
| Continuous Operations Profit Margin | 4.18% | -2.02% | -13.48% | -22.29% | -18.03% |
| Net Income Per EBT | 86.99% | 42.80% | 83.72% | 118.65% | 70.61% |
| EBT Per EBIT | 183.60% | -81.50% | 176.48% | 163.40% | 259.66% |
| Return on Assets (ROA) | 4.83% | -0.78% | -12.91% | -21.68% | -14.06% |
| Return on Equity (ROE) | 11.23% | -2.85% | -46.55% | -74.34% | -65.21% |
| Return on Capital Employed (ROCE) | 5.06% | 4.19% | -20.18% | -21.60% | -15.77% |
| Return on Invested Capital (ROIC) | 2.79% | 2.96% | -10.02% | -15.03% | -8.11% |
| Return on Tangible Assets | 5.08% | -0.83% | -13.87% | -23.36% | -15.52% |
| Earnings Yield | 2.39% | -1.39% | -16.25% | -19.88% | -12.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 10.48 | 8.68 | 9.07 | 10.28 | 9.77 |
| Payables Turnover | 7.37 | 8.01 | 7.83 | 8.71 | 8.89 |
| Inventory Turnover | 3.50 | 4.34 | 4.65 | 4.09 | 4.13 |
| Fixed Asset Turnover | 2.57 | 2.78 | 2.34 | 2.50 | 2.26 |
| Asset Turnover | 0.99 | 1.04 | 0.98 | 0.97 | 0.79 |
| Working Capital Turnover Ratio | -29.86 | -8.80 | -8.28 | -13.17 | -78.03 |
| Cash Conversion Cycle | 89.52 | 80.63 | 72.17 | 82.92 | 84.76 |
| Days of Sales Outstanding | 34.84 | 42.05 | 40.26 | 35.50 | 37.35 |
| Days of Inventory Outstanding | 104.19 | 84.14 | 78.55 | 89.35 | 88.48 |
| Days of Payables Outstanding | 49.50 | 45.56 | 46.64 | 41.92 | 41.07 |
| Operating Cycle | 139.02 | 126.19 | 118.81 | 124.85 | 125.82 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 630.95 | 1012.92 | -1354.62 | -2032.37 | -477.86 |
| Free Cash Flow Per Share | 176.60 | 509.82 | -2027.52 | -2776.57 | -1309.91 |
| Dividend Paid and CapEx Coverage Ratio | 1.39 | 2.00 | -2.00 | -2.71 | -0.57 |
| Capital Expenditure Coverage Ratio | 1.39 | 2.01 | -2.01 | -2.73 | -0.57 |
| Operating Cash Flow Coverage Ratio | 0.13 | 0.14 | -0.17 | -0.26 | -0.05 |
| Operating Cash Flow to Sales Ratio | 0.03 | 0.05 | -0.06 | -0.08 | -0.02 |
| Free Cash Flow Yield | 0.46% | 4.33% | -11.28% | -10.23% | -3.90% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 40.87 | -71.93 | -6.15 | -5.03 | -8.02 |
| Price-to-Sales (P/S) Ratio | 2.04 | 0.53 | 0.81 | 1.12 | 1.43 |
| Price-to-Book (P/B) Ratio | 4.69 | 2.05 | 2.86 | 3.74 | 5.23 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 218.01 | 23.09 | -8.86 | -9.78 | -25.65 |
| Price-to-Operating Cash Flow Ratio | 61.02 | 11.62 | -13.27 | -13.36 | -70.31 |
| Price-to-Earnings Growth (PEG) Ratio | -0.06 | 0.76 | 0.13 | -0.18 | -0.01 |
| Enterprise Value Multiple | 31.12 | 13.76 | -12.59 | -10.82 | -8.78 |
| Enterprise Value | 1.24T | 462.04B | 645.20B | 870.84B | 889.75B |
| EV to EBITDA | 31.12 | 13.76 | -12.59 | -10.82 | -8.78 |
| EV to Sales | 2.19 | 0.75 | 1.07 | 1.37 | 1.59 |
| EV to Free Cash Flow | 234.12 | 32.45 | -11.77 | -11.91 | -28.56 |
| EV to Operating Cash Flow | 65.53 | 16.33 | -17.62 | -16.27 | -78.28 |
| Tangible Book Value Per Share | 7015.21 | 4464.36 | 4889.19 | 5735.78 | 3950.29 |
| Shareholders’ Equity Per Share | 8204.50 | 5755.34 | 6272.39 | 7259.48 | 6428.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.25 | -0.16 | 0.14 | -0.19 | 0.28 |
| Revenue Per Share | 18875.77 | 22015.64 | 22225.60 | 24207.20 | 23549.78 |
| Net Income Per Share | 921.07 | -163.83 | -2920.02 | -5396.66 | -4191.94 |
| Tax Burden | 0.87 | 0.43 | 0.84 | 1.19 | 0.71 |
| Interest Burden | 1.84 | -1.40 | 1.19 | 1.09 | 1.08 |
| Research & Development to Revenue | 0.06 | 0.08 | 0.16 | 0.17 | 0.17 |
| SG&A to Revenue | 0.14 | 0.15 | 0.14 | 0.17 | 0.17 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.69 | -2.28 | 0.46 | 0.38 | 0.11 |
Currency in KRW

